Company Overview and News

 
Ellis drops to fifth spot on Nagambie Resources' wild ride

2018-04-21 theage.com.au
Angie Ellis of 80 20 Investments, who was leading in week one of the four-week race, has dropped to fifth place in week two.

 
Ellis drops to fifth spot on Nagambie Resources' wild ride

2018-04-21 smh.com.au
Angie Ellis of 80 20 Investments, who was leading in week one of the four-week race, has dropped to fifth place in week two.

 
Ellis starts new race where she left off - in first place

2018-04-14 smh.com.au
Straight after winning the last Shares Race, Angie Ellis of 80 20 Investments starts the new four-week race in the lead, with her original $100,000 portfolio worth $108,192.

 
Leigh Creek gas injunction flagged

2017-10-06 perthnow.com.au
INDIGENOUS groups in the Leigh Creek area are considering lodging a court injunction to block the “dirty, filthy business” of underground coal gasification going ahead in the area.

 
Leigh Creek Energy gets ready to raise

2017-03-22 proactiveinvestors.com.au
Leigh Creek Energy (ASX:LCK) has been granted a trading halt by the ASX, pending details of a capital raising. The halt will remain in place until the opening of trade on Monday 27th March 2017, or earlier if an announcement is made to the market.

 
Leigh Creek Energy secures $4M facility to advance syngas project

2017-02-09 proactiveinvestors.com.au
Leigh Creek Energy (ASX:LCK) has established a $4 million research and development working capital facility with the Commonwealth Bank of Australia (ASX:CBA).

 
Leigh Creek Energy to begin syngas pre-feasibility studies on a positive note

2017-01-30 proactiveinvestors.com.au
Leigh Creek Energy (ASX:LCK) has completed a successful scoping study for the Leigh Creek Energy Project (LCEP) in South Australia and has now commenced a pre-feasibility study.

 
Project milestone for Leigh Creek

2016-11-16 perthnow.com.au
THE company behind an underground coal gasification project in the state’s north has awarded the first contract for the development of its pilot plant.

 
Leigh Creek Energy Ltd on track to build pre-commercial energy plant

2016-11-15 proactiveinvestors.com.au
The LCEP will produce high value products such as electricity, methane and fertiliser from the remnant coal resources of the Leigh Creek coal mine utilising in-situ gasification technologies. Leigh Creek Energy has awarded the contract for the design of the thermal oxidiser and cold vent package to Gasco Pty Ltd, a leading combustion and process engineering company. The thermal oxidiser will dispose of syngas and associated condensate products produced during the pre-commercial stage of the LCEP.

 
Leigh Creek Energy commences drilling operations

2016-07-05 energyglobal
Leigh Creek Energy has announced the commencement of drilling operations at the Leigh Creek site. The drilling programme will initially comprise 3 drill holes that will continue to enhance and validate the models at the preferred Pre-Commercial Gas Demonstration Facility site, while obtaining required environmental data. The data collected will include:

 
Leigh Creek Energy Ltd drilling ahead at gasification project

2016-07-05 proactiveinvestors.com.au
Leigh Creek Energy Ltd (ASX:LCK) is focussed on developing its Leigh Creek Energy Project in South Australia.

 
Appendix 3B

2016-05-13 asx.com.au

 
Change in substantial holding

2016-05-12 asx.com.au

 
Change in substantial holding

2016-05-12 asx.com.au

 
Appendix 3B and LR 3.10.5A Notice

2016-05-09 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...